Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial

The Lancet Oncology 2026

View at publisher
Authors: Mark D Tyson, Jong-Kil Nam, Shreyas S Joshi, Edward M. Uchio, Seung Il Jung, Trinity J. Bivalacqua, Gary D. Steinberg, Neal D Shore, James M. Burke, Hiroshi Kitamura, Ben Tran, Roger Li
DOI: 10.1016/s1470-2045(26)00194-4
Cited by: 5
References: 21

Fields of Study & Subjects

Bladder and Urothelial Cancer Treatments Immune responses and vaccinations Urinary and Genital Oncology Studies

Publication details

Journal / source
The Lancet Oncology
Publisher
Elsevier BV
Volume
27
Issue
8
Pages
983–993
Publication date
27 July 2026
Language
EN